APGE

NEUTRALM&A

Apogee Therapeutics, Inc.

2026-08-19

Price

$134.71

+0.10%

This is the 2026-08-19 snapshot — the signals and analysis for APGE as of this single trading day.

View full APGE research hub →

Score13.0Priority

Signals6/8 DNA2/13 Act · 1/4 Risk

SentimentNEUTRALScore: 8

Volume1.1xvs 20d avg

Analysis

Apogee Therapeutics (APGE) is trading purely as a merger arbitrage following AbbVie's agreement to acquire the company for $135.11 per share in cash. The stock's ultra-low 1.7% realized volatility and technical signals like QUIET_STORM and STEADY_CLIMB perfectly reflect this price anchoring to the definitive buyout offer. Furthermore, the current RISK_ON macro regime and dropping Treasury yields have provided an ideal backdrop for deal financing, directly enabling AbbVie's successful $8 billion debt offering this week to fund the transaction.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSMARKET LEADERPERFECT STACKQUIET ACCUMULATIONSELLER FATIGUEWEAK FINISH

Key Takeaways

Actionable Thesis: APGE is a highly stable merger arbitrage hold, trading just pennies below the $135.11 cash acquisition price [1.1.7].
Key Risk: Regulatory pushback or an unexpected antitrust block, which would collapse the deal and send the stock plummeting to its pre-deal valuation.
What to Watch: Final shareholder and regulatory approvals, as AbbVie has already secured the necessary debt financing.

← Back to 2026-08-19 View Full APGE History →Yahoo Finance &nearr;